IN2012DN03310A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03310A
IN2012DN03310A IN3310DEN2012A IN2012DN03310A IN 2012DN03310 A IN2012DN03310 A IN 2012DN03310A IN 3310DEN2012 A IN3310DEN2012 A IN 3310DEN2012A IN 2012DN03310 A IN2012DN03310 A IN 2012DN03310A
Authority
IN
India
Prior art keywords
moeties
peptiod
tetrapeptide
tripeptide
dipeptide
Prior art date
Application number
Other languages
English (en)
Inventor
Guido Franzoso
Albert Andrzej Jaxa-Chamiec
Caroline Minli Rachel Low
Simona Maria Monti
Menotti Ruvo
Laura Tornatore
Catherine Jane Tralau-Stewart
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of IN2012DN03310A publication Critical patent/IN2012DN03310A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • C07K5/06113Asp- or Asn-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN3310DEN2012 2009-10-22 2010-10-22 IN2012DN03310A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918579.4A GB0918579D0 (en) 2009-10-22 2009-10-22 Gadd45beta targeting agents
PCT/GB2010/001970 WO2011048390A2 (en) 2009-10-22 2010-10-22 Gadd45beta targeting agents

Publications (1)

Publication Number Publication Date
IN2012DN03310A true IN2012DN03310A (enExample) 2015-10-23

Family

ID=41426579

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3310DEN2012 IN2012DN03310A (enExample) 2009-10-22 2010-10-22

Country Status (14)

Country Link
US (2) US8993717B2 (enExample)
EP (2) EP2491051A2 (enExample)
JP (2) JP5961113B2 (enExample)
KR (1) KR20120099440A (enExample)
CN (1) CN102741269B (enExample)
AU (1) AU2010309594B2 (enExample)
BR (1) BR112012011332B1 (enExample)
CA (2) CA3034860A1 (enExample)
GB (1) GB0918579D0 (enExample)
IL (1) IL219325B (enExample)
IN (1) IN2012DN03310A (enExample)
MX (1) MX357801B (enExample)
RU (2) RU2577311C2 (enExample)
WO (1) WO2011048390A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
GB201107118D0 (en) * 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
KR101745766B1 (ko) * 2011-10-14 2017-06-09 서울대학교산학협력단 펩타이드 나노구조체 및 그 제조 방법
EP3777876B1 (en) * 2011-10-28 2023-08-09 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc COMPOSITION AND METHODS FOR CELLULAR MODULATION
CN104817618B (zh) * 2014-01-30 2018-07-03 陈光健 寡肽cd01及其制备方法和应用
CN104817616A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd02及其制备方法和应用
GB201414542D0 (en) * 2014-08-15 2014-10-01 Imp Innovations Ltd Novel therapy
CN111606972B (zh) * 2019-01-30 2022-04-05 浙江省医学科学院 一种鳕鱼皮寡肽及其分离纯化和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用
RU2716258C1 (ru) * 2019-07-30 2020-03-11 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Пептидный антагонист нмда-рецептора
KR102417496B1 (ko) * 2019-11-29 2022-07-06 (주)수파드엘릭사 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
KR102348728B1 (ko) * 2020-03-23 2022-01-12 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
WO2021194228A1 (ko) * 2020-03-23 2021-09-30 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
WO2022203219A1 (ko) * 2021-03-22 2022-09-29 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
US20230159587A1 (en) * 2021-03-22 2023-05-25 L-Base Co., Ltd. Pharmaceutical composition for preventing or treating cancer
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
IT202100023357A1 (it) * 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
KR102786112B1 (ko) * 2021-09-17 2025-03-27 주식회사 엘베이스 항암제의 항암 효과 증진용 약학적 조성물
WO2023043261A1 (ko) * 2021-09-17 2023-03-23 주식회사 엘베이스 항암제의 항암 효과 증진용 약학적 조성물
KR102494749B1 (ko) * 2021-09-17 2023-02-06 주식회사 엘베이스 암 치료용 cage 저해제에 대한 반응자 특성화 방법
US20250213645A1 (en) * 2021-09-17 2025-07-03 L-Base Co., Ltd. Pharmaceutical composition for modulating immune response
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
CN116350746B (zh) * 2023-05-16 2024-03-22 海口桥水联合科技有限责任公司 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用
CN119874809A (zh) * 2025-01-13 2025-04-25 广东工业大学 一类抗氧化肽及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
HU187461B (en) * 1981-10-22 1986-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing n-nitrozo-n-bracket-beta-chloroethyl-bracket closed-carbamoyl-peptides of citostatic activity
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
DE3813989A1 (de) * 1987-04-29 1988-11-10 Hoechst Ag Peptide mit phospholipase a(pfeil abwaerts)2(pfeil abwaerts)-hemmender wirkung
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US20030162223A1 (en) * 1999-10-22 2003-08-28 Lowery David E. Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CA2447314A1 (en) * 2001-05-15 2002-11-21 Atsuro Nakazato Arginine derivatives
PT1790655E (pt) 2001-07-13 2010-07-09 Cms Peptides Patent Holding Co PéPTIDOS BIOLOGICAMENTE ACTIVOS
WO2003028659A2 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7354898B2 (en) * 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
JP2006506975A (ja) 2002-08-19 2006-03-02 イェン、ユン 肝疾患の治療
EP1615954A2 (en) 2003-04-22 2006-01-18 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
ES2412483T3 (es) * 2005-01-13 2013-07-11 University Of Wollongong Derivados antibióticos de binaftilo
SI1853620T1 (sl) * 2005-02-09 2012-03-30 Helix Biomedix Inc Antimikrobni heksapeptidi
WO2006105811A1 (en) * 2005-04-07 2006-10-12 Centre National De La Recherche Scientifique Compounds useful as modulators of the proteasome activity
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7951782B2 (en) * 2005-09-29 2011-05-31 Maruha Nichiro Seafoods, Inc Composition effective to prevent or treat adult disease
JP2007217358A (ja) * 2006-02-17 2007-08-30 Nippon Meat Packers Inc 抗酸化性ペプチド
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
CA2659655A1 (en) * 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
CN101153053B (zh) * 2006-09-28 2012-02-01 中国医学科学院药物研究所 骨生肽、其制备方法和其药物组合物与用途
EP1964560A1 (en) 2007-02-28 2008-09-03 Helmholtz-Zentrum für Infektionsforschung GmbH Use of inhibitors of the degradation of p27 for the treatment of cancer
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
EP2390662A1 (en) 2010-05-27 2011-11-30 Erasmus University Medical Center Rotterdam Molecular classification of multiple myeloma

Also Published As

Publication number Publication date
JP2016166211A (ja) 2016-09-15
EP2491051A2 (en) 2012-08-29
KR20120099440A (ko) 2012-09-10
WO2011048390A3 (en) 2011-11-03
US20150368294A1 (en) 2015-12-24
RU2016102083A (ru) 2018-11-20
EP3178836A1 (en) 2017-06-14
RU2577311C2 (ru) 2016-03-20
JP2013508346A (ja) 2013-03-07
CA2778236A1 (en) 2011-04-28
GB0918579D0 (en) 2009-12-09
BR112012011332B1 (pt) 2022-07-05
IL219325A0 (en) 2012-06-28
WO2011048390A2 (en) 2011-04-28
EP3178836B1 (en) 2019-12-25
US20120277164A1 (en) 2012-11-01
CA3034860A1 (en) 2011-04-28
CN102741269B (zh) 2017-08-29
US9518083B2 (en) 2016-12-13
JP5961113B2 (ja) 2016-08-02
MX2012004755A (es) 2012-11-22
BR112012011332A2 (pt) 2016-11-22
CN102741269A (zh) 2012-10-17
AU2010309594A1 (en) 2012-05-17
US8993717B2 (en) 2015-03-31
AU2010309594B2 (en) 2016-01-07
RU2012120905A (ru) 2013-11-27
IL219325B (en) 2019-02-28
MX357801B (es) 2018-07-25

Similar Documents

Publication Publication Date Title
IN2012DN03310A (enExample)
PH12014500053A1 (en) Proteasome inhibitors
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
PH12012500916B1 (en) Treatments for gastrointestinal disorders
IN2012MN02591A (enExample)
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
EP4269563A3 (en) Anti-gd2 antibodies
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
MX2011007930A (es) Conjugados de insulina cristalina.
PH12012501943A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
PH12018500640A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
ZA201004480B (en) Methods and compositions for oral administration of protein and peptide therapeutic agents
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12012501389A1 (en) Hedgehog inhibitors
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EP1993523A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
WO2014039074A3 (en) Therapeutic compositions and related methods